Firefly Neuroscience is trading 5.4% down at $1.05, with the decline most consistent with healthcare-sector pressure as insurance concerns weigh on hospitals and healthcare profitability.
- No fresh company-specific announcement was identified for September 9, 2026.
- Available coverage points to earlier developments, including an August shareholder-approved plan and capital-structure changes, rather than a new catalyst.
- Healthcare ETF XLV is down 2.19%; broader indexes are only modestly lower, making sector sentiment the stronger explanation.